Bruker (BRKR)
Health Care · Scientific analytical instruments and life sciences research equipment
Bruker is a global leader in high-performance analytical instrumentation and diagnostic solutions for life sciences and materials research, enabling structural biology, drug discovery, and scientific innovation at molecular levels.
What Bruker does
Bruker develops, manufactures, and distributes high-performance scientific instruments and analytical/diagnostic solutions for detecting, measuring, and visualizing structural characteristics of chemical, biological, and industrial materials at microscopic, molecular, and cellular levels. The company serves life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, built on technology platforms including magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology, and molecular spectroscopy.
Themes: ["Structural proteomics and drug discovery","Preclinical imaging and in-vivo imaging","Pharmaceutical and biotechnology research instrumentation","Materials science and chemical analysis","Clinical microbiology and diagnostics","Spatial and single-cell biology","Lab automation and digital transformation","Multiomics and proteomics research"]
Fundamentals
- Price$60.58 as of 2026-07-09 close
- Market cap$9.1B as of 2026-07-10
- 1-year return+43.8% as of 2026-07-09 close
- Net margin-0.3% as of 2026-07-10
- Gross margin+46.7% as of 2026-07-10
- ROE-0.5% as of 2026-07-10
- Debt / equity0.68 as of 2026-07-10
- Revenue growth (YoY)+0.4% as of 2026-07-10
- Revenue CAGR (3y)+10.7% SEC XBRL
- Beta1.27 as of 2026-07-10
Dividend: yield +0.3%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Highly competitive markets with established rivals in analytical instrumentation, microscopy, and diagnostics; pressure on pricing and product differentiation","Dependence on academic and pharmaceutical research funding; downturns in R&D spending or pharmaceutical innovation cycles could reduce customer demand","Complex global supply chain and manufacturing operations; exposure to currency fluctuations, geopolitical tensions, and supply disruptions affecting margins"]
Competitors & peers
- Thermo Fisher Scientific (TMFX)
- Agilent Technologies (A)
- PerkinElmer (PKI)
- Waters Corporation (WAT)
- Shimadzu
- JEOL
- Rigaku
- Leica Microsystems
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.